{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:16:19Z","timestamp":1793798179325,"version":"4.6.1"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.<\/jats:p>","DOI":"10.3389\/fpubh.2023.1274719","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:13:42Z","timestamp":1706156022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Opioid use disorder: current trends and potential treatments"],"prefix":"10.3389","volume":"11","author":[{"given":"Yu Kyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis K.","family":"Thanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Fuehrlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"117137","DOI":"10.1016\/j.jns.2020.117137","article-title":"Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): do homo sapiens acquire or have a reward deficiency syndrome?","volume":"418","author":"Gold","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15761\/jsin.1000227","article-title":"Calvin klein (CK) designer cocktail, new \u201cspeedball\u201d is the \u201cgrimm reaper\u201d: brain dopaminergic surge a potential death sentence","volume":"7","author":"Gold","year":"2020","journal-title":"J Syst Integr Neurosci"},{"key":"ref3","first-page":"99","article-title":"The role of alcohol, drugs, and deaths of despair in the U.S.'s falling life expectancy","volume":"117","author":"Gold","year":"2020","journal-title":"Mo Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/appi.ajp.2021.21030320","article-title":"Risks and benefits of Cannabis and cannabinoids in psychiatry","volume":"179","author":"Hill","year":"2022","journal-title":"Am J Psychiatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"ref6","year":"2021"},{"key":"ref7","article-title":"Provisional drug overdose death counts","volume-title":"National Center for Health Statistics","author":"Ahmad","year":""},{"key":"ref8","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.drugalcdep.2020.108176","article-title":"Signal of increased opioid overdose during COVID-19 from emergency medical services data","volume":"214","author":"Slavova","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: opioid use disorder and COVID-19","volume":"173","author":"Alexander","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","article-title":"COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States","volume":"26","author":"Wang","year":"2021","journal-title":"Mol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/ADM.0000000000000684","article-title":"Opioid use disorder and COVID-19: crashing of the crises","volume":"14","author":"Khatri","year":"2020","journal-title":"J Addict Med"},{"key":"ref12","article-title":"Deaths, despair tied to drug dependence are accelerating amid COVID-19","author":"Gold","year":"2020"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMc1809521","article-title":"Lethal fentanyl and cocaine intoxication","volume":"379","author":"Khatri","year":"2018","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ajad.13087","article-title":"Brief report: rates of fentanyl use among psychiatric emergency room patients","volume":"30","author":"Elmarasi","year":"2021","journal-title":"Am J Addict"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e192851","DOI":"10.1001\/jamanetworkopen.2019.2851","article-title":"Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine","volume":"2","author":"LaRue","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","article-title":"Modeling health benefits and harms of public policy responses to the US opioid epidemic","volume":"108","author":"Pitt","year":"2018","journal-title":"Am J Public Health"},{"key":"ref18","author":"Gold","year":"2020"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e210242","DOI":"10.1001\/jamanetworkopen.2021.0242","article-title":"Assessment of annual cost of substance use disorder in US hospitals","volume":"4","author":"Peterson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.biopsych.2020.06.023","article-title":"Converging structural and functional evidence for a rat salience network","volume":"88","author":"Tsai","year":"2020","journal-title":"Biol Psychiatry"},{"key":"ref22","author":"Mann","year":"2021"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/appi.ajp.2019.19121245","article-title":"Discontinuing buprenorphine treatment of opioid use disorder: what do we (not) know?","volume":"177","author":"Connery","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"108196","DOI":"10.1016\/j.jsat.2020.108196","article-title":"Medication treatment for opioid use disorder in the age of COVID-19: can new regulations modify the opioid cascade?","volume":"122","author":"Nunes","year":"2021","journal-title":"J Subst Abus Treat"},{"key":"ref26","first-page":"1","article-title":"Naltrexone: a history and future directions","author":"Srivastava","year":"2018","journal-title":"Cerebrum"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00213-006-0670-2","article-title":"The effects of buprenorphine on fentanyl withdrawal in rats","volume":"191","author":"Bruijnzeel","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"116718","DOI":"10.1016\/j.jns.2020.116718","article-title":"Treatment resistant opioid use disorder (TROUD): definition, rationale, and recommendations","volume":"411","author":"Wolf","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of XR-NTX versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15761\/JSIN.1000229","article-title":"Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual","volume":"6","author":"Blum","year":"2020","journal-title":"J Syst Integr Neurosci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15761\/JSIN.1000211","article-title":"Death by opioids: are there non-addictive scientific solutions?","volume":"5","author":"Downs","year":"2019","journal-title":"J Syst Integr Neurosci"},{"key":"ref33","article-title":"How to combat the global opioid crisis","volume":"5","author":"Dennen","year":"2023","journal-title":"CPQ Neurol Psychol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"Substance Use Addict"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e69043","DOI":"10.1371\/journal.pone.0069043","article-title":"Long term suboxone\u2122 emotional reactivity as measured by automatic detection in speech","volume":"8","author":"Hill","year":"2013","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jpsychires.2021.10.011","article-title":"Reduced midbrain functional connectivity and recovery in abstinent heroin users","volume":"144","author":"Xu","year":"2021","journal-title":"J Psychiatr Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/00325481.2015.994879","article-title":"rsfMRI effects of KB220Z\u2122 on neural pathways in reward circuitry of abstinent genotyped heroin addicts","volume":"127","author":"Blum","year":"2015","journal-title":"Postgrad Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"116763","DOI":"10.1016\/j.jns.2020.116763","article-title":"The therapeutic potential of exercise for neuropsychiatric diseases: a review","volume":"412","author":"Swenson","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.17756\/jrds.2015-008","article-title":"The molecular neurobiology of twelve steps program & fellowship: connecting the dots for recovery","volume":"1","author":"Blum","year":"2015","journal-title":"J Reward Defic Syndr"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2022.1652","article-title":"Preaddiction-a missing concept for treating substance use disorders","volume":"79","author":"McLellan","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm12111772","article-title":"Genetic addiction risk and psychological profiling analyses for \"Preaddiction\"","volume":"12","author":"Blum","year":"2022","journal-title":"Severity Index J Pers Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","article-title":"Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region - United States, 2006-2015","volume":"66","author":"O'Donnell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/cercor\/bhv335","article-title":"Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex","volume":"27","author":"Renard","year":"2017","journal-title":"Cereb Cortex"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17756\/jas.2020-043","article-title":"Addiction by any other name is still addiction: embracing molecular neurogenetic\/epigenetic basis of reward deficiency","volume":"6","author":"Edwards","year":"2020","journal-title":"J Addict Sci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neubiorev.2020.04.021","article-title":"Pre-clinical models of reward deficiency syndrome: a behavioral octopus","volume":"115","author":"Gondr\u00e9-Lewis","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"108514","DOI":"10.1016\/j.jsat.2021.108514","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms","volume":"132","author":"Treitler","year":"2022","journal-title":"J Subst Abus Treat"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jama.2021.1741","article-title":"Overcoming barriers to treatment of opioid use disorder","volume":"325","author":"Olsen","year":"2021","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jama.2021.0958","article-title":"Removing one barrier to opioid use disorder treatment: is it enough?","volume":"325","author":"Weimer","year":"2021","journal-title":"JAMA"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.annemergmed.2021.04.023","article-title":"Consensus recommendations on the treatment of opioid use disorder in the emergency department","volume":"78","author":"Hawk","year":"2021","journal-title":"Ann Emerg Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e2117128","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency Department for Treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref54","first-page":"1","article-title":"Insurance companies fighting the peer review empire without any validity: the case for addiction and pain modalities in the face of an American drug epidemic","volume":"1","author":"Blum","year":"2018","journal-title":"SEJ Surg Pain"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s11606-021-06904-4","article-title":"Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment","volume":"36","author":"Taylor","year":"2021","journal-title":"J Gen Intern Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0149-7634(85)90022-3","article-title":"New concepts in cocaine addiction: the dopamine depletion hypothesis","volume":"9","author":"Dackis","year":"1985","journal-title":"Neurosci Biobehav Rev"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"120404","DOI":"10.1016\/j.jns.2022.120404","article-title":"Why haven't we solved the addiction crisis?","volume":"442","author":"Blum","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2741\/4509","article-title":"Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome","volume":"22","author":"Febo","year":"2017","journal-title":"Front Biosci"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41398-021-01542-0","article-title":"Drug addiction: from bench to bedside","volume":"11","author":"Cheron","year":"2021","journal-title":"Transl Psychiatry"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11065-018-9393-5","article-title":"Efficacy of invasive and non-invasive brain modulation interventions for addiction","volume":"29","author":"Luigjes","year":"2019","journal-title":"Neuropsychol Rev"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"114904","DOI":"10.1016\/j.psychres.2022.114904","article-title":"High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex reduces drug craving and improves decision-making ability in methamphetamine use disorder","volume":"317","author":"Wang","year":"2022","journal-title":"Psychiatry Res"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.biopsych.2013.01.003","article-title":"Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving","volume":"73","author":"Li","year":"2013","journal-title":"Biol Psychiatry"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neubiorev.2019.06.007","article-title":"Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead","volume":"104","author":"Ekhtiari","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.biopsych.2014.05.020","article-title":"Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial","volume":"76","author":"Dinur-Klein","year":"2014","journal-title":"Biol Psychiatry"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.euroneuro.2017.03.008","article-title":"Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake","volume":"27","author":"Addolorato","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pnpbp.2013.10.019","article-title":"Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients","volume":"49","author":"Prikryl","year":"2014","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.euroneuro.2015.11.011","article-title":"Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: a pilot study","volume":"26","author":"Terraneo","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"102809","DOI":"10.1016\/j.ebiom.2020.102809","article-title":"The effects of repetitive transcranial magnetic stimulation on cue-induced craving in male patients with heroin use disorder","volume":"56","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm11030624","article-title":"Repetitive transcranial magnetic stimulation (rTMS) as a promising treatment for craving in stimulant drugs and Behavioral addiction: a Meta-analysis","volume":"11","author":"Gay","year":"2022","journal-title":"J Clin Med"},{"key":"ref72","author":"Sahlem","year":"2023"},{"key":"ref73","article-title":"Repetitive transcranial magnetic stimulation to reduce heroin cravings U.S","author":"Lee","year":"2022"},{"key":"ref74","author":"Hanlon","year":"2023"},{"key":"ref75","author":"Voineskos","year":"2022"},{"key":"ref76","author":"Greenwald","year":"2023"},{"key":"ref77","author":"Greenwald","year":"2023"},{"key":"ref78","author":"Rush","year":"2023"},{"key":"ref79","author":"Wang","year":"2020"},{"key":"ref80","author":"Haroun","year":"2022"},{"key":"ref81","author":"Mahoney","year":"2023"},{"key":"ref82","author":"Biernacki","year":"2023"},{"key":"ref83","author":"Mcrae-Clark","year":"2022"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"173240","DOI":"10.1016\/j.pbb.2021.173240","article-title":"Treating cocaine and opioid use disorder with transcranial magnetic stimulation: a path forward","volume":"209","author":"Steele","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"e27360","DOI":"10.5812\/traumamon.27360","article-title":"Magnetic resonance therapy improves clinical phenotype and EEG alpha power in posttraumatic stress disorder","volume":"20","author":"Taghva","year":"2015","journal-title":"Trauma Mon"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s10143-020-01415-y","article-title":"Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review","volume":"44","author":"Hassan","year":"2021","journal-title":"Neurosurg Rev"},{"key":"ref87","author":"Brown","year":"2023"},{"key":"ref88","author":"Sun","year":"2020"},{"key":"ref89","author":"Lu","year":"2018"},{"key":"ref90","author":"Luming","year":"2016"},{"key":"ref91","author":"Kuhn","year":"2016"},{"key":"ref92","author":"Tomycz","year":"2023"},{"key":"ref93","author":"Gao","year":"2016"},{"key":"ref94","author":"Gao","year":"2014"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1056\/NEJMoa1600159","article-title":"A randomized trial of focused ultrasound thalamotomy for essential tremor","volume":"375","author":"Elias","year":"2016","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial","volume":"74","author":"Bond","year":"2017","journal-title":"JAMA Neurol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/da.23004","article-title":"A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes","volume":"37","author":"Razza","year":"2020","journal-title":"Depress Anxiety"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fnins.2017.00641","article-title":"Transcranial direct current stimulation (tDCS): a Beginner's guide for design and implementation","volume":"11","author":"Thair","year":"2017","journal-title":"Front Neurosci"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1073858410386614","article-title":"Physiological basis of transcranial direct current stimulation","volume":"17","author":"Stagg","year":"2011","journal-title":"Neuroscientist"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.brs.2011.03.002","article-title":"Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions","volume":"5","author":"Brunoni","year":"2012","journal-title":"Brain Stimul"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.brs.2008.06.004","article-title":"Transcranial direct current stimulation: state of the art 2008","volume":"1","author":"Nitsche","year":"2008","journal-title":"Brain Stimul"},{"key":"ref102","year":"2023"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Therap"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"112628","DOI":"10.1016\/j.bbr.2020.112628","article-title":"Ketamine and rapid acting antidepressants: are we ready to cure, rather than treat depression?","volume":"390","author":"Abdallah","year":"2020","journal-title":"Behav Brain Res"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00406-021-01267-7","article-title":"Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies","volume":"272","author":"Rodrigues","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of Esketamine nasal spray plus Oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated Oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7554\/eLife.70148","article-title":"Where ketamine and dopamine collide","volume":"10","author":"Marcus","year":"2021","journal-title":"Elife"},{"key":"ref113","year":"2022"},{"key":"ref114","year":"2021"},{"key":"ref115","author":"Fischer","year":""},{"key":"ref116","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcph.1995","article-title":"MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with Meta-analysis","volume":"62","author":"Smith","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref118","year":"2023"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in Cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey","volume":"10","author":"Garcia-Romeu","year":"2019","journal-title":"Front Psych"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh","year":"2021","journal-title":"BJPsych Open"},{"key":"ref124","author":"Khawaja","year":"2023"},{"key":"ref125","author":"Garland","year":"2023"},{"key":"ref126","author":"Jones","year":"2023"},{"key":"ref127","author":"Belcher","year":"2023"},{"key":"ref128","author":"Brown","year":"2023"},{"key":"ref129","author":"Johnson","year":"2023"},{"key":"ref130","author":"Louw","year":"2023"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes","volume":"4","author":"Agin-Liebes","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/2054.2020.00133","article-title":"Novel treatment of opioid use disorder using ibogaine and iboga in two adults","volume":"4","author":"Wilson","year":"2020","journal-title":"J Psychedel Stud"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine","volume":"50","author":"Malcolm","year":"2018","journal-title":"J Psychoactive Drugs"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0099-9598(01)56012-5","article-title":"Ibogaine in the treatment of heroin withdrawal","volume":"56","author":"Mash","year":"2001","journal-title":"Alkaloids Chem Biol"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/15672050113109990001","article-title":"Ibogaine in the treatment of substance dependence","volume":"6","author":"Brown","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"650785","DOI":"10.3389\/fnins.2021.650785","article-title":"Neuroimmune mechanisms as novel treatment targets for substance use disorders and associated comorbidities","volume":"15","author":"Namba","year":"2021","journal-title":"Front Neurosci"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nn.2250","article-title":"N-acetylcysteine reverses cocaine-induced metaplasticity","volume":"12","author":"Moussawi","year":"2009","journal-title":"Nat Neurosci"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biopsych.2009.07.018","article-title":"Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking","volume":"67","author":"Knackstedt","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/npp.2014.14","article-title":"Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2","volume":"39","author":"Abulseoud","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1038\/s41380-022-01736-y","article-title":"Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Mol Psychiatry"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2174\/1871527314666150529132503","article-title":"Targeting the toll of drug abuse: the translational potential of toll-like receptor 4","volume":"14","author":"Bachtell","year":"2015","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1021\/acschemneuro.9b00225","article-title":"Methamphetamine activates toll-like receptor 4 to induce central immune Signaling within the ventral tegmental area and contributes to extracellular dopamine increase in the nucleus Accumbens Shell","volume":"10","author":"Wang","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1523\/JNEUROSCI.0684-12.2012","article-title":"Opioid activation of toll-like receptor 4 contributes to drug reinforcement","volume":"32","author":"Hutchinson","year":"2012","journal-title":"J Neurosci"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"120098","DOI":"10.1016\/j.jns.2021.120098","article-title":"Current status of vaccines for substance use disorders: a brief review of human studies","volume":"434","author":"Truong","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopsych.2009.08.031","article-title":"Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans","volume":"67","author":"Haney","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","article-title":"Animal models and the development of vaccines to treat substance use disorders","volume":"126","author":"Ohia-Nwoko","year":"2016","journal-title":"Int Rev Neurobiol"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14329","article-title":"Current status of immunotherapies for addiction","volume":"1489","author":"Xu","year":"2021","journal-title":"Ann N Y Acad Sci"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Hum Vaccin Immunother"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1274719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:13:54Z","timestamp":1706156034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1274719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":154,"alternative-id":["10.3389\/fpubh.2023.1274719"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1274719","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"article-number":"1274719"}}